Jimenez-Quevedo P, et al. - In this posthoc subanalysis of the EXAMINATION trial, researchers compared 5-year outcomes between 258 diabetics vs 1,239 nondiabetics with ST-segment elevation myocardial infarction (STEMI) who received treatment with a second-generation drug-eluting stent, to determine the long term effect of diabetes in STEMI patients. In the trial, 1,497 patients were included, of whom 137 diabetics received everolimus-eluting stent (EES) and 121 were treated with bare-metal stent (BMS), whereas, 613 nondiabetics received EES and 626 received BMS. Up to 5-years, they assessed patient-oriented combined endpoint (POCE), including all-cause death, any MI or any revascularization, as well as other clinical parameters. Findings revealed worse clinical outcomes post-STEMI among diabetics vs nondiabetics, these worse outcomes were essentially attributed to atherosclerosis progression. Diabetics treated with EES demonstrated no attenuation in the rate of POCE at 5-years, however, had reduced revascularization need compared with BMS.